Lack of evidence for increased inhibitor incidence in patients switched from plasma-derived to recombinant factor VIII
- 12 July 2001
- journal article
- review article
- Published by Wiley in Haemophilia
- Vol. 7 (4), 346-348
- https://doi.org/10.1046/j.1365-2516.2001.00515.x
Abstract
De novo inhibitor development is a rare event in PTPs switched from pdFVIII to rFVIII. Based on previously published data of clinical studies a change in FVIII product is unlikely to provoke inhibitor formation.Keywords
This publication has 21 references indexed in Scilit:
- High responding factor VIII inhibitors in mild Haemophilia - is there a link with recent changes in clinical practice?Haemophilia, 2000
- Incidence of inhibitors in haemophilia A patients – a review of recent studies of recombinant and plasma‐derived factor VIII concentratesHaemophilia, 1999
- Frequent but low titre factor VIII inhibitors in haemophilia A patients treated with high purity concentratesBlood Coagulation & Fibrinolysis, 1999
- Inhibitor Development in a Multitransfused Patient with Severe Haemophilia AThrombosis and Haemostasis, 1999
- Neutrophil 5-nucleotidase reaction in chronic myelogenous leukemia, myelofibrosis with myeloid metaplasia, and polycythemia veraAnnals of Hematology, 1998
- Is a Change of Factor VIII Product a Risk Factor for the Development of a Factor VIII Inhibitor?Thrombosis and Haemostasis, 1998
- Second Generation, B-Domain Deleted Recombinant Factor VIIIThrombosis and Haemostasis, 1997
- A Multicenter Pharmacosurveillance Study for the Evaluation of the Efficacy and Safety of Recombinant Factor VIII in the Treatment of Patients with Hemophilia AThrombosis and Haemostasis, 1997
- A sudden increase in factor VIII inhibitor development in multitransfused hemophilia A patients in The Netherlands. Dutch Hemophilia Study GroupBlood, 1993
- Human Recombinant DNA–Derived Antihemophilic Factor (Factor VIII) in the Treatment of Hemophilia ANew England Journal of Medicine, 1990